Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Propionyl-L-carnitine

L R Wiseman1, R N Brogden

  • 1Adis International Limited, Auckland, New Zealand.

Drugs & Aging
|April 16, 1998
PubMed
Summary
This summary is machine-generated.

Propionyl-L-carnitine enhances muscle energy production and improves walking distance in patients with peripheral arterial disease. This treatment is well-tolerated and shows significant benefits for quality of life.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trastuzumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.

Drugs·2000
Same author

Docetaxel: an update of its use in advanced breast cancer.

Drugs·2000
Same author

Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.

Drugs·2000
Same author

Epirubicin: a review of its intravesical use in superficial bladder cancer.

Drugs & aging·1999
Same author

Exemestane.

Drugs·1999
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
See all related articles

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Peripheral arterial disease (PAD) is characterized by impaired blood flow to the limbs.
  • Ischaemia in PAD reduces muscle energy production and walking capacity.
  • Current treatments have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To evaluate the efficacy of propionyl-L-carnitine in improving muscle energy metabolism and functional capacity in patients with PAD.
  • To assess the impact of propionyl-L-carnitine on blood viscosity and coagulative-fibrinolytic homeostasis.
  • To determine the safety and tolerability of propionyl-L-carnitine therapy.

Main Methods:

  • Double-blind, multicentre phase III studies involving patients with peripheral arterial obstructive disease (Fontaine Leriche stage II) and intermittent claudication.

Related Experiment Videos

  • Administration of oral propionyl-L-carnitine (1 to 3 g/day) or placebo.
  • Assessment of maximum walking distance (MWD) using treadmill tests and evaluation of quality of life.

    • Main Results:

    • Propionyl-L-carnitine significantly increased mitochondrial oxidative adenosine triphosphate (ATP) synthesis and pyruvate dehydrogenase activity in ischaemic muscles.
    • Mean MWD improved significantly more with propionyl-L-carnitine compared to placebo (33-73% vs 21-50% improvement).
    • Patients with baseline MWD < 250m experienced significant quality of life improvements with propionyl-L-carnitine therapy.

    Conclusions:

    • Propionyl-L-carnitine effectively improves muscle energy production and enhances walking distance in patients with PAD.
    • The drug demonstrates beneficial effects on blood viscosity and coagulative-fibrinolytic balance.
    • Propionyl-L-carnitine is well-tolerated, with a safety profile comparable to placebo.